{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T16:37:31Z","timestamp":1783528651353,"version":"3.55.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2023,4,16]],"date-time":"2023-04-16T00:00:00Z","timestamp":1681603200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,4,16]],"date-time":"2023-04-16T00:00:00Z","timestamp":1681603200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Medizinische Hochschule Hannover (MHH)"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2023,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Few studies assessed the effect of nusinersen on respiratory function in adult patients with spinal muscular atrophy (SMA). The aim of this single-center study was to analyze pulmonary function and its association with muscle function and quality of life (QoL) in adult patients with 5q-SMA under nusinersen.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We recorded forced vital capacity (FVC), forced expiratory volume in the first second (FEV1) and peak expiratory flow (PEF) during nusinersen treatment in 38 adult SMA patients. Revised Upper Limb Module (RULM), Hammersmith Functional Motor Scale Expanded (HFMSE), 36-Item Short Form Health Survey (SF-36) questionnaire and Fatigue Severity Scale (FSS) were recorded and correlations between muscle function, QoL, fatigue and respiratory parameters were analyzed.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>No differences were detected between mean FVC, FEV1, PEF at different timepoints versus baseline. Ambulatory patients showed significant improvement in mean PEF at month 30, compared to non-ambulatory patients (+\u20090.8\u2009\u00b1\u20090.5 vs. \u2212\u20090.0\u2009\u00b1\u20090.5, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.05). Patients with fatigue at baseline showed significant improvement in mean PEF at month 10, compared to patients without fatigue at baseline (+\u20090.6\u2009\u00b1\u20090.9 vs. \u2212\u20090.4\u2009\u00b1\u20090.5, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.05). Physical domains of SF-36 positively correlated with the change in FVC and FEV1. FSS negatively correlated with the change in mean PEF.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Mean pulmonary function remained stable during nusinersen treatment over a period of up to 30\u00a0months. Improvement in pulmonary function was associated with improvement in motor function, fatigue and QoL, early after nusinersen initiation.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00415-023-11711-4","type":"journal-article","created":{"date-parts":[[2023,4,16]],"date-time":"2023-04-16T15:02:02Z","timestamp":1681657322000},"page":"3616-3622","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["An observational cohort study on pulmonary function in adult patients with 5q-spinal muscular atrophy under nusinersen therapy"],"prefix":"10.1007","volume":"270","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1783-703X","authenticated-orcid":false,"given":"Bogdan","family":"Bjelica","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camilla","family":"Wohnrade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alma","family":"Osmanovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivia","family":"Schreiber-Katz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"Petri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,4,16]]},"reference":[{"issue":"5","key":"11711_CR1","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1212\/CON.0000000000000918","volume":"26","author":"JR Nance","year":"2020","unstructured":"Nance JR (2020) Spinal muscular atrophy. Continuum 26(5):1348\u20131368. https:\/\/doi.org\/10.1212\/CON.0000000000000918","journal-title":"Continuum"},{"issue":"1","key":"11711_CR2","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/0092-8674(95)90460-3","volume":"80","author":"S Lefebvre","year":"1995","unstructured":"Lefebvre S, B\u00fcrglen L, Reboullet S, Clermont O, Burlet P, Viollet L, Benichou B, Cruaud C, Millasseau P, Zeviani M (1995) Identification and characterization of a spinal muscular atrophy-determining gene. Cell 80(1):155\u2013165. https:\/\/doi.org\/10.1016\/0092-8674(95)90460-3","journal-title":"Cell"},{"issue":"9630","key":"11711_CR3","doi-asserted-by":"publisher","first-page":"2120","DOI":"10.1016\/s0140-6736(08)60921-6","volume":"371","author":"MR Lunn","year":"2008","unstructured":"Lunn MR, Wang CH (2008) Spinal muscular atrophy. Lancet 371(9630):2120\u20132133. https:\/\/doi.org\/10.1016\/s0140-6736(08)60921-6","journal-title":"Lancet"},{"issue":"3","key":"11711_CR4","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.nmd.2017.11.004","volume":"28","author":"RS Finkel","year":"2018","unstructured":"Finkel RS, Mercuri E, Meyer OH, Simonds AK, Schroth MK, Graham RJ, Kirschner J, Iannaccone ST, Crawford TO, Woods S, Muntoni F, Wirth B, Montes J, Main M, Mazzone ES, Vitale M, Snyder B, Quijano-Roy S, Bertini E, Davis RH, Qian Y, Sejersen T, Care SMA (2018) Diagnosis and management of spinal muscular atrophy: Part 2: Pulmonary and acute care; medications, supplements and immunizations; other organ systems; and ethics. Neuromuscul Disord 28(3):197\u2013207. https:\/\/doi.org\/10.1016\/j.nmd.2017.11.004","journal-title":"Neuromuscul Disord"},{"issue":"1","key":"11711_CR5","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s13023-020-01367-y","volume":"15","author":"CA Wijngaarde","year":"2020","unstructured":"Wijngaarde CA, Veldhoen ES, van Eijk RPA, Stam M, Otto LAM, Asselman FL, W\u00f6sten-van Asperen RM, Hulzebos EHJ, Verweij-van den Oudenrijn LP, Bartels B, Cuppen I, Wadman RI, van den Berg LH, van der Ent CK, van der Pol WL (2020) Natural history of lung function in spinal muscular atrophy. Orphanet J Rare Dis 15(1):88. https:\/\/doi.org\/10.1186\/s13023-020-01367-y","journal-title":"Orphanet J Rare Dis"},{"issue":"4","key":"11711_CR6","doi-asserted-by":"publisher","first-page":"e587","DOI":"10.1212\/WNL.0000000000011051","volume":"96","author":"F Trucco","year":"2021","unstructured":"Trucco F, Ridout D, Scoto M, Coratti G, Main ML, Muni Lofra R, Mayhew AG, Montes J, Pane M, Sansone V, Albamonte E, D\u2019Amico A, Bertini E, Messina S, Bruno C, Parasuraman D, Childs AM, Gowda V, Willis T, Ong M, Marini-Bettolo C, De Vivo DC, Darras BT, Day J, Kichula EA, Mayer OH, Navas Nazario AA, Finkel RS, Mercuri E, Muntoni F (2021) Respiratory trajectories in type 2 and 3 spinal muscular atrophy in the iSMAC cohort study. Neurology 96(4):e587\u2013e599. https:\/\/doi.org\/10.1212\/WNL.0000000000011051","journal-title":"Neurology"},{"issue":"7","key":"11711_CR7","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1056\/NEJMoa1710504","volume":"378","author":"E Mercuri","year":"2018","unstructured":"Mercuri E, Darras BT, Chiriboga CA, Day JW, Campbell C, Connolly AM, Iannaccone ST, Kirschner J, Kuntz NL, Saito K, Shieh PB, Tulinius M, Mazzone ES, Montes J, Bishop KM, Yang Q, Foster R, Gheuens S, Bennett CF, Farwell W, Schneider E, De Vivo DC, Finkel RS (2018) Nusinersen versus sham control in later-onset spinal muscular atrophy. N Engl J Med 378(7):625\u2013635. https:\/\/doi.org\/10.1056\/NEJMoa1710504","journal-title":"N Engl J Med"},{"issue":"18","key":"11711_CR8","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1056\/NEJMoa1702752","volume":"377","author":"RS Finkel","year":"2017","unstructured":"Finkel RS, Mercuri E, Darras BT, Connolly AM, Kuntz NL, Kirschner J, Chiriboga CA, Saito K, Servais L, Tizzano E, Topaloglu H, Tulinius M, Montes J, Glanzman AM, Bishop K, Zhong ZJ, Gheuens S, Bennett CF, Schneider E, Farwell W, De Vivo DC (2017) Nusinersen versus sham control in infantile-onset spinal muscular atrophy. N Engl J Med 377(18):1723\u20131732. https:\/\/doi.org\/10.1056\/NEJMoa1702752","journal-title":"N Engl J Med"},{"issue":"21","key":"11711_CR9","doi-asserted-by":"publisher","first-page":"e2492","DOI":"10.1212\/WNL.0000000000007527","volume":"92","author":"BT Darras","year":"2019","unstructured":"Darras BT, Chiriboga CA, Iannaccone ST, Swoboda KJ, Montes J, Mignon L, Xia S, Bennett CF, Bishop KM, Shefner JM, Green AM, Sun P, Bhan I, Gheuens S, Schneider E, Farwell W, De Vivo DC (2019) Nusinersen in later-onset spinal muscular atrophy: Long-term results from the phase 1\/2 studies. Neurology 92(21):e2492\u2013e2506. https:\/\/doi.org\/10.1212\/WNL.0000000000007527","journal-title":"Neurology"},{"issue":"4","key":"11711_CR10","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/S1474-4422(20)30037-5","volume":"19","author":"T Hagenacker","year":"2020","unstructured":"Hagenacker T, Wurster CD, G\u00fcnther R, Schreiber-Katz O, Osmanovic A, Petri S, Weiler M, Ziegler A, Kuttler J, Koch JC, Schneider I, Wunderlich G, Schloss N, Lehmann HC, Cordts I, Deschauer M, Lingor P, Kamm C, Stolte B, Pietruck L, Totzeck A, Kizina K, M\u00f6nninghoff C, von Velsen O, Ose C, Reichmann H, Forsting M, Pechmann A, Kirschner J, Ludolph AC, Hermann A, Kleinschnitz C (2020) Nusinersen in adults with 5q spinal muscular atrophy: a non-interventional, multicentre, observational cohort study. Lancet Neurol 19(4):317\u2013325. https:\/\/doi.org\/10.1016\/S1474-4422(20)30037-5","journal-title":"Lancet Neurol"},{"issue":"1","key":"11711_CR11","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1136\/thoraxjnl-2020-216564","volume":"77","author":"A Chacko","year":"2022","unstructured":"Chacko A, Sly PD, Ware RS, Begum N, Deegan S, Thomas N, Gauld LM (2022) Effect of nusinersen on respiratory function in paediatric spinal muscular atrophy types 1\u20133. Thorax 77(1):40\u201346. https:\/\/doi.org\/10.1136\/thoraxjnl-2020-216564","journal-title":"Thorax"},{"issue":"4","key":"11711_CR12","doi-asserted-by":"publisher","first-page":"453","DOI":"10.3233\/JND-190416","volume":"6","author":"MC Walter","year":"2019","unstructured":"Walter MC, Wenninger S, Thiele S, Stauber J, Hiebeler M, Greckl E, Stahl K, Pechmann A, Lochm\u00fcller H, Kirschner J, Schoser B (2019) Safety and treatment effects of nusinersen in longstanding adult 5q-SMA type 3\u2014a prospective observational study. J Neuromuscul Dis 6(4):453\u2013465. https:\/\/doi.org\/10.3233\/JND-190416","journal-title":"J Neuromuscul Dis"},{"issue":"11","key":"11711_CR13","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1136\/jnnp-2020-323822","volume":"91","author":"L Maggi","year":"2020","unstructured":"Maggi L, Bello L, Bonanno S, Govoni A, Caponnetto C, Passamano L, Grandis M, Trojsi F, Cerri F, Ferraro M, Bozzoni V, Caumo L, Piras R, Tanel R, Saccani E, Meneri M, Vacchiano V, Ricci G, Soraru\u2019 G, D\u2019Errico E, Tramacere I, Bortolani S, Pavesi G, Zanin R, Silvestrini M, Politano L, Schenone A, Previtali SC, Berardinelli A, Turri M, Verriello L, Coccia M, Mantegazza R, Liguori R, Filosto M, Marrosu G, Siciliano G, Simone IL, Mongini T, Comi G, Pegoraro E (2020) Nusinersen safety and effects on motor function in adult spinal muscular atrophy type 2 and 3. J Neurol Neurosurg Psychiatry 91(11):1166\u20131174. https:\/\/doi.org\/10.1136\/jnnp-2020-323822","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"3","key":"11711_CR14","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1007\/s00415-020-10223-9","volume":"268","author":"B De Wel","year":"2021","unstructured":"De Wel B, Goosens V, Sobota A, Van Camp E, Geukens E, Van Kerschaver G, Jagut M, Claes K, Claeys KG (2021) Nusinersen treatment significantly improves hand grip strength, hand motor function and MRC sum scores in adult patients with spinal muscular atrophy types 3 and 4. J Neurol 268(3):923\u2013935. https:\/\/doi.org\/10.1007\/s00415-020-10223-9","journal-title":"J Neurol"},{"issue":"3","key":"11711_CR15","doi-asserted-by":"publisher","first-page":"e317","DOI":"10.1212\/CPJ.0000000000001033","volume":"11","author":"T Duong","year":"2021","unstructured":"Duong T, Wolford C, McDermott MP, Macpherson CE, Pasternak A, Glanzman AM, Martens WB, Kichula E, Darras BT, De Vivo DC, Zolkipli-Cunningham Z, Finkel RS, Zeineh M, Wintermark M, Sampson J, Hagerman KA, Young SD, Day JW (2021) Nusinersen treatment in adults with spinal muscular atrophy. Neurol Clin Pract 11(3):e317\u2013e327. https:\/\/doi.org\/10.1212\/CPJ.0000000000001033","journal-title":"Neurol Clin Pract"},{"key":"11711_CR16","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0199657","volume":"13","author":"MP McDermott","year":"2018","unstructured":"McDermott MP, Mirek E, Mazzone ES, Main M, Glanzman AM, Duong T, Young SD, Salazar R, Pasternak A et al (2018) Ambulatory function in spinal muscular atrophy: age-related patterns of progression. PLoS ONE 13:e0199657. https:\/\/doi.org\/10.1371\/journal.pone.0199657","journal-title":"PLoS ONE"},{"key":"11711_CR17","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1183\/09041950.005s1693","volume":"16","author":"PH Quanjer","year":"1993","unstructured":"Quanjer PH, Tammeling GJ, Cotes JE, Pedersen OF, Peslin R, Yernault JC (1993) Lung volumes and forced ventilatory flows. Report working party standardization of lung function tests, European Community for Steel and Coal. Official statement of the European Respiratory Society. Eur Respir J Suppl 16:5\u201340","journal-title":"Eur Respir J Suppl"},{"issue":"6","key":"11711_CR18","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1002\/mus.25430","volume":"55","author":"ES Mazzone","year":"2017","unstructured":"Mazzone ES, Mayhew A, Montes J, Ramsey D, Fanelli L, Young SD, Salazar R, De Sanctis R, Pasternak A, Glanzman A, Coratti G, Civitello M, Forcina N, Gee R, Duong T, Pane M, Scoto M, Pera MC, Messina S, Tennekoon G, Day JW, Darras BT, De Vivo DC, Finkel R, Muntoni F, Mercuri E (2017) Revised upper limb module for spinal muscular atrophy: development of a new module. Muscle Nerve 55(6):869\u2013874. https:\/\/doi.org\/10.1002\/mus.25430","journal-title":"Muscle Nerve"},{"key":"11711_CR19","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/s1090-3798(03)00060-6","volume":"7","author":"M Main","year":"2003","unstructured":"Main M, Kairon H, Mercuri E, Muntoni F (2003) The Hammersmith functional motor scale for children with spinal muscular atrophy: a scale to test ability and monitor progress in children with limited ambulation. Eur J Paediatr Neurol 7:155\u2013159. https:\/\/doi.org\/10.1016\/s1090-3798(03)00060-6","journal-title":"Eur J Paediatr Neurol"},{"issue":"10","key":"11711_CR20","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1001\/archneur.1989.00520460115022","volume":"46","author":"LB Krupp","year":"1989","unstructured":"Krupp LB, LaRocca NG, Muir-Nash J, Steinberg AD (1989) The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol 46(10):1121\u20131123. https:\/\/doi.org\/10.1001\/archneur.1989.00520460115022","journal-title":"Arch Neurol"},{"key":"11711_CR21","unstructured":"SF-36 Health Survey (original version) language recalls. http:\/\/www.qualitymetric.com. Accessed Nov 2018"},{"issue":"7","key":"11711_CR22","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1097\/00002060-200207000-00007","volume":"81","author":"AA Su\u00e1rez","year":"2002","unstructured":"Su\u00e1rez AA, Pessolano FA, Monteiro SG, Ferreyra G, Capria ME, Mesa L, Dubrovsky A, De Vito EL (2002) Peak flow and peak cough flow in the evaluation of expiratory muscle weakness and bulbar impairment in patients with neuromuscular disease. Am J Phys Med Rehabil 81(7):506\u2013511. https:\/\/doi.org\/10.1097\/00002060-200207000-00007","journal-title":"Am J Phys Med Rehabil"},{"issue":"3","key":"11711_CR23","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1007\/s00415-020-10227-5","volume":"268","author":"C Binz","year":"2021","unstructured":"Binz C, Schreiber-Katz O, Kumpe M, Ranxha G, Siegler H, Wieselmann G, Petri S, Osmanovic A (2021) An observational cohort study on impact, dimensions and outcome of perceived fatigue in adult 5q-spinal muscular atrophy patients receiving nusinersen treatment. J Neurol 268(3):950\u2013962. https:\/\/doi.org\/10.1007\/s00415-020-10227-5","journal-title":"J Neurol"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-023-11711-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-023-11711-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-023-11711-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,14]],"date-time":"2023-06-14T16:05:15Z","timestamp":1686758715000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-023-11711-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,16]]},"references-count":23,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["11711"],"URL":"https:\/\/doi.org\/10.1007\/s00415-023-11711-4","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,16]]},"assertion":[{"value":"3 March 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 April 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 April 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"AO has received honoraria as a speaker\/consultant from the German Neuromuscular Society \u201cDeutsche Gesellschaft fuer Muskelkranke (DGM e.V.) and Biogen GmbH. OS-K received academic research support from the Hannover Medical School (MHH) Young Faculty Program, 2018\u20132020, the \u201cEllen-Schmidt-Program\u2014Habilitationsfoerderung fuer Wissenschaftlerinnen\u201d, MHH (2021), and the German Neuromuscular Society \u201cDeutsche Gesellschaft fuer Muskelkranke\u201d (DGM e.V.), 2019\u20132021 (Grant no. Sc 23\/1); and received honoraria as a speaker\/consultant and\/or funding for travel expenses from the German Neuromuscular Society \u201cDeutsche Gesellschaft fuer Muskelkranke (DGM e.V.), Biogen GmbH, Biermann Verlag GmbH, and MK\u2009+\u2009S\u2014Medizin, Kommunikation & Service GmbH, outside the submitted work. SP has received speaker fees, non-financial support and research support from Biogen, Roche, AL-S Pharma, Amylyx, Cytokinetics, Ferrer, ITF-Pharma, and Sanofi and served on advisory boards of Amylyx, Biogen, Roche, Zambon and ITF Pharma outside of the submitted work. BB, CW and AO declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The study was approved by the Ethical Board of Hannover Medical School (no. 6269) and all patients gave their written informed consent to participate.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical standards"}}]}}